2019年2月19日 · A newly published study suggests the long-acting buprenorphine formulation BUP-XR is more effective than placebo in helping patients struggling with addiction to opioids. BUP-XR is a monthly extended-release injection.

This real-world evaluation of XR-BUP in a low-threshold clinic found that treatment was feasible, well tolerated, and outcomes were good, with most individuals choosing to continue treatment and a majority with no evidence of ongoing opioid use or precipitated withdrawal.

BUP-XR is a potentially “game-changing” medication that, in a single injection, provides a month of potent withdrawal suppression, craving control, and protection from overdose. We now offer BUP-XR to all of our patients on 16mg SL BUP or greater. The logistic requirements and overall burden of clinical care is drastically reduced using BUP ...

2019年2月23日 · BUP-XR provides sustained buprenorphine plasma concentrations to block drug-liking of abused opioids over the entire monthly dosing period, while controlling withdrawal and craving symptoms. Administration of BUP-XR in a health-care setting also mitigates abuse, misuse, diversion, and unintentional exposure.

BUP-XR (a.k.a. RBP-6000 or SUBLOCADE™) is an extended-release subcutaneous buprenorphine formulation for the treatment of opioid use disorder. BUP-XR was designed to provide sustained buprenorphine exposure throughout the monthly dosing interval, at ...

2023年1月2日 · Objectives: This open-label, single-group, single-center pilot study (NCT03993392) evaluated safety and tolerability of initiating BUP-XR following a single BUP-TM 4 mg dose. Methods: Eligible participants abstained from short and long-acting opioids for 6 and 24 hours, respectively.

2023年12月2日 · BUP-XR (SUBLOCADE ®) is the first buprenorphine extended-release subcutaneous injection approved in the USA for monthly treatment of moderate-to-severe opioid use disorder (OUD). Among patients with OUD, those who inject or use high doses of opioids likely require higher doses of buprenorphine to maximize treatment efficacy.

BUP-XR (RBP-6000 or SUBLOCADE) is the first Food and Drug Administration–approved subcutaneously administered monthly extended-release buprenorphine medication for the treatment of moderate or severe opioid use disorder. The primary objective of this phase III study was to assess the long-term safety, tolerability, and efficacy of BUP-XR. Methods

2023年1月1日 · Extended-release buprenorphine (BUP-XR) is a subcutaneous monthly depot injection used to treat opioid use disorder. In 2018, Health Canada approved the only BUP-XR treatment available in Canada, under the brand name Sublocade.

2019年3月4日 · BUP-XR was shown to produce significantly higher percentage abstinence and treatment success versus placebo; treatment outcomes were consistent across other efficacy endpoints including control of opioid craving and withdrawal symptoms.